Vanda ’s latest study failed. But revenue grew in 2019.

The D.C. biotech ’s phase 3 clinical trial of a drug candidate failed to reduce symptoms among adult patients with an itchy skin condition called atopic dermatitis.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Itch in atopic dermatitis (AD) is aggravated under warm conditions. Transient receptor potential vanilloid 3 (TRPV3), a member of the thermosensitive TRP channels, is activated by innocuous heat and is abundantly expressed in keratinocytes. The potential role of TRPV3 in itch is illustrated in TRPV3 channelopathies of human and mice. However, the role of TRPV3 in heat-induced itch in AD and the underlying mechanisms are unclear. Here we showed that keratinocytes isolated from patients with AD exhibit enhanced expression and heat sensitivity with hyperactive channel function of TRPV3.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
Conditions:   Atopic Dermatitis;   Pruritus;   Pruritus Chronic;   Dermatitis Interventions:   Drug: Naltrexone;   Other: Placebo Sponsor:   University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Itch, initiated by the activation of sensory neurons, is frequently associated with dermatological diseases. MrgprA3+ sensory neurons have been identified as one of the major itch-sensing neuronal populations. Mounting evidence has demonstrated that peripheral pathological conditions induce physiological regulations of sensory neurons, which is critical for the maintenance of chronic itch sensation. However, the underlying molecular mechanisms are not clear. Here we performed RNA sequencing of genetically labeled MrgprA3+ neurons under both na ïve and allergic contact dermatitis conditions.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
lsh S Abstract We were fascinated and heartened to read this very helpful commentary1 on the study by Redhu et al2 who describe some precise physico-biological pathways that link skin barrier disruption to itch in atopic dermatitis (AD). This may well explain how curtailing scratching in AD with the simple behavioural technique of habit reversal can so dramatically improve the condition3. It is important to note that scratching in AD over time often becomes not only a response to itch, but also to both habit and mental state. PMID: 32222068 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
ConclusionsQualitative data from NLP, being more patient-centric than data from clinical standardized measures, provide a more comprehensive view of the burden of AD to inform disease management.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
March 18, 2020 -- Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
Abstract BACKGROUND: Little is known about the measurement properties of Patient-Oriented Scoring Atopic Dermatitis (PO-SCORAD) in adults with AD. Even less is known about how PO-SCORAD performs compared to the Patient-Oriented Eczema Measure (POEM). OBJECTIVE: To examine the measurement properties of PO-SCORAD and compare them with POEM. METHODS: A prospective dermatology-practice based study of 291 AD patients (age 1872 years). RESULTS: PO-SCORAD and POEM were moderately correlated with each other (Spearman rho=0.56); had weak-moderate correlations with Numeric Rating Scale (NRS) worst-itch and av...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Ann Allergy Asthma Immunol Source Type: research
CONCLUSIONS: The Group here presents and discusses the consensus based recommendation statements on adult atopic dermatitis. PMID: 32163045 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Contributors : Liang Han ; Jingjing YangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe performed RNA sequencing of genetically labeled MrgprA3+ neurons under both na ïve and allergic contact dermatitis conditions. Our results revealed the unique molecular signature of itch-sensing neurons and the distinct transcriptional profile changes that result in response to dermatitis. We found enrichment of nine Mrgpr family members and two histamine receptors in MrgprA3 + neurons, suggesting that MrgprA3+ neurons are a direct neuronal target for histamine and Mrgprs agonists. In addit...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
In this study, we investigated the mechanisms for the activation of itch-responsive GRPR+ neurons in the spinal dorsal horn (SDH). GRPR+ neurons expressed the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) containing the GluR2 subunit. In mice, peripherally elicited histaminergic and non-histaminergic itch was prevented by intrathecal (i.t.) administration of the AMPAR antagonist NBQX, which was consistent with the fact that firing of GRPR+ neurons in SDH under histaminergic and non-histaminergic itch was completely blocked by NBQX, but not by the GRPR antagonist RC-3095. Because GRP+ neurons i...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Neuropharmacology Source Type: research
More News: Biotechnology | Clinical Trials | Dermatitis | Dermatology | Health Management | Itchiness | Pharmaceuticals | Skin | Study